Aims: To assess the extent to which patients with type 2 diabetes or prediabetes, obesity (BMI 30-45kg/m²) and moderate OSA requiring continuous positive airway pressure ventilation (CPAP) are able to discontinue CPAP following EB-related weight loss (ISRCTN33788132).

Methods: We assessed Apnoea Hypopnoea Index (AHI), weight and HbA1c before and following EB. The full study involves 18 patients receiving EB for up to 1 year with 1 year follow-up.

Results: We report here the 1st 11 patients {9/11 (82%) female, 9/11 (82%) type 2 diabetes, 2/11 (18%) prediabetes, mean ± SD age 52.6 ± 9.7 years} to reach at least 3 months EB treatment. In 3 months, weight fell by 6.9 ± 3.3kg from 103.7 ± 14.8 to 96.8 ± 14.8kg (p<0.001), mean BMI by 2.5 ± 1.3kg/m² from 37.1 ± 3.6 to 34.6 ± 3.7kg/m² (p<0.001), mean HbA1c by 0.9±1.0% from 8.0±3.8 to 7.1±3.7% (p=0.025). OSA improved (Figure). Prior to EB, all 11 patients had AHI in moderate sleep apnoea range (15-29.9 events/hour). Following EB, the AHI of 7/11(64%) patients fell below the moderate sleep apnoea threshold of 15 events/hour, such that they no longer required CPAP. Of the remaining 4 patients, 1 came off CPAP at 6 months.

Conclusion: These preliminary results are encouraging in that EB has already allowed 8/11(73%) patients to discontinue CPAP, in addition to glycaemic and weight benefits. Discontinuing CPAP is beneficial to health services but especially to patients.
graphic
View largeDownload slide
Disclosure

M. Yadagiri: None. F.Y. Kinney: None. N. Ashman: None. M.H. Lang: None. E. Fogden: None. M. Anderson: None. J. Bleasdale: None. C. Walton: None. M.A. Greenstone: None. R.E. Ryder: Other Relationship; Self; AstraZeneca. Speaker's Bureau; Self; Bioquest, Janssen Pharmaceuticals, Inc.. Other Relationship; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Novo Nordisk A/S.

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.